9.715

2.03% 0.205

Corbus Pharmaceuticals Holdings Inc (CRBP)

Overview News Price History Financials Discussions Forecast Stock Split

Corbus Pharmaceuticals Holdings Inc stock is traded at $9.715, with a volume of 121.52K. It is up +2.03% in the last 24 hours and up +0.23% over the past month. Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Previous Close:

$9.51

Open:

$9.51

24h Volume:

121.52K

Relative Volume:

0.26

Market Cap:

$187.03M

Revenue:

$1.54M

Net Income/Loss:

$-84.53M

P/E Ratio:

-1.6708

EPS:

-5.8145

Net Cash Flow:

$-73.65M

1W Performance:

+1.39%

1M Performance:

+0.23%

6M Performance:

+23.92%

1Y Performance:

+8.29%

1-Day Range:

$9.40

$9.91

1-Week Range:

$9.18

$10.25

52-Week Range:

$7.12

$20.56

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile

Name

Corbus Pharmaceuticals Holdings Inc

Sector

Healthcare (1085)

Industry

Biotechnology (602)

Phone

617-963-0103

Address

500 RIVER RIDGE DRIVE, NORWOOD, MA

Employee

Twitter

@corbuspharma

Next Earnings Date

2026-08-04

Latest SEC Filings

CRBP's Discussions on Twitter

Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRBP Corbus Pharmaceuticals Holdings Inc	9.67	183.94M	1.54M	-84.53M	-73.65M	-5.8145
VRTX Vertex Pharmaceuticals Inc	530.00	134.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	795.39	82.06B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	873.64	54.10B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	206.91	44.06B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	358.14	40.64B	5.76B	514.49M	1.10B	4.4813

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-30-25	Resumed	B. Riley Securities	Buy
Feb-28-25	Initiated	William Blair	Outperform
Dec-02-24	Initiated	Piper Sandler	Overweight
Jul-30-24	Initiated	Wedbush	Outperform
Jul-22-24	Resumed	H.C. Wainwright	Buy
Jun-26-24	Initiated	B. Riley Securities	Buy
Jun-03-24	Reiterated	Oppenheimer	Outperform
May-13-24	Initiated	RBC Capital Mkts	Outperform
Mar-06-24	Upgrade	Jefferies	Hold → Buy
Sep-08-20	Downgrade	BTIG Research	Buy → Neutral
Sep-08-20	Downgrade	Jefferies	Buy → Hold
Sep-08-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Sep-08-20	Downgrade	ROTH Capital	Buy → Neutral
Jul-07-20	Initiated	ROTH Capital	Buy
Jun-17-20	Initiated	BTIG Research	Buy
Mar-26-20	Initiated	Nomura	Buy
Apr-05-19	Initiated	Jefferies	Buy
Mar-20-19	Initiated	Oppenheimer	Outperform
Jan-11-19	Reiterated	Cantor Fitzgerald	Overweight
Dec-26-18	Initiated	H.C. Wainwright	Buy
Dec-07-18	Initiated	RBC Capital Mkts	Outperform
Oct-24-18	Initiated	B. Riley FBR	Buy
Jan-19-18	Initiated	Raymond James	Outperform
Dec-14-17	Reiterated	Cantor Fitzgerald	Overweight
Nov-08-17	Reiterated	Noble Financial	Buy
Sep-29-17	Resumed	Noble Financial	Buy
Mar-30-17	Reiterated	Cantor Fitzgerald	Overweight
Nov-15-16	Reiterated	JMP Securities	Mkt Outperform
Nov-11-16	Reiterated	Noble Financial	Buy

View All

Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News

Aug 11, 2026

Research Analysts Set Expectations for CRBP Q3 Earnings - MarketBeat

Aug 11, 2026

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Aug 11, 2026

Aug 10, 2026

Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch

Aug 10, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) CEO Yuval Cohen Sells 17,000 Shares of Stock - MarketBeat

Aug 10, 2026

Sean Moran Sells 12,000 Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) Stock - MarketBeat

Aug 10, 2026

Aug 08, 2026

Corbus Pharmaceuticals Holdings Inc Actuals & Estimates (NASDAQ:CRBP) - TradingView

Aug 08, 2026

Corbus Pharmaceuticals (NASDAQ:CRBP) Cut to "Strong Sell" at Wall Street Zen - MarketBeat

Aug 08, 2026

Aug 07, 2026

Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch

Aug 07, 2026

Oppenheimer Issues Pessimistic Forecast for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat

Aug 07, 2026

CRBP Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus

Aug 07, 2026

Oppenheimer Adjusts PT on Corbus Pharmaceuticals to $48 From $52, Maintains Outperform Rating - marketscreener.com

Aug 07, 2026

H.C. Wainwright Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating, Maintains Target Price $35 - moomoo.com

Aug 07, 2026

HC Wainwright Has Lowered Expectations for Corbus Pharmaceuticals (NASDAQ:CRBP) Stock Price - MarketBeat

Aug 07, 2026

Aug 06, 2026

William Blair Maintains Corbus Pharmaceuticals(CRBP.US) With Buy Rating - moomoo.com

Aug 06, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) ramps R&D to $51M as cash backs key trials - Stock Titan

Aug 06, 2026

Corbus Pharmaceuticals Holdings, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 06, 2026

Form 8K Corbus Pharmaceuticals Holding For: 6 August By Investing.com - Investing.com Nigeria

Aug 06, 2026

Corbus Pharmaceuticals (NASDAQ: CRBP) doubles Q2 loss while securing FDA clearance for Phase 3 trial - Stock Titan

Aug 06, 2026

Corbus Pharmaceuticals: Q2 Earnings Snapshot - marketscreener.com

Aug 06, 2026

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update - finance.yahoo.com

Aug 06, 2026